Keyword Search
 
2017 | 2016 | 2015 | 2014
DateTitle 
12/14/16Newly Published Data Reinforce Growing Body of Evidence Supporting Cidara Therapeutics’ Lead Antifungal CD101
Data Showcase Compound’s Discovery through Development and Potential to Expand Echinocandin Utility Across Multiple Infectious-Disease Indications SAN DIEGO--(BUSINESS WIRE)--Dec. 14, 2016-- Cidara Therapeutics, Inc. (Nasdaq:CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced that data from preclinical and clinical studies evaluating the company’s novel echinocandin antifungal CD101 appear... 
11/28/16Cidara Therapeutics’ Presentations at ASH 2016 to Highlight Potential Role of Novel Antifungal CD101 in Patients with Hematologic Malignancies
SAN DIEGO--(BUSINESS WIRE)--Nov. 28, 2016-- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced that data from preclinical and clinical studies evaluating its novel echinocandin antifungal CD101 will be presented at the 58th American Society of Hematology (ASH) Annual Meeting and Exposition taking place in San Diego from December 3-6, 2016. CD101 is Cidara’s ... 
11/10/16Cidara Provides Corporate Update and Reports Third Quarter 2016 Financial Results
SAN DIEGO, Nov. 10, 2016 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq:CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today reported financial results for the three months ended September 30, 2016 and provided an update on its corporate activities and product pipeline. “Cidara made major progress in the third quarter and achieved significant clinical and corporate milestones. We enrolled the first patient in our Phase 2 STRIVE study of CD1... 
11/10/16Cidara Therapeutics to Present Data on Novel Antifungal CD101 at the Global Joint Conference of ICHS and INFOCUS
Data Will Highlight the Potential Broad Clinical Utility and Subcutaneous Administration of CD101 for Invasive Fungal Infections SAN DIEGO--(BUSINESS WIRE)--Nov. 10, 2016-- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced that data from preclinical and clinical studies evaluating its novel echinocandin antifungal CD101 as a potential treatment for inva... 
11/08/16Cidara Therapeutics to Present at the Stifel 2016 Healthcare Conference
SAN DIEGO, Nov. 08, 2016 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq:CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced it will participate in the Stifel 2016 Healthcare Conference on Tuesday, November 15, 2016. Jeffrey Stein, Ph.D., president and chief executive officer of Cidara, is scheduled to present at 8:00 a.m. EST (5:00 a.m. PST). The conference is being held in New York City. A live audio webcast and replay will be a... 
11/02/16Cidara Therapeutics and Square 1 Bank Announce $20 Million Credit Facility
SAN DIEGO, Nov. 02, 2016 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq:CDTX), a biotechnology company developing novel anti-infectives and immunotherapies to treat fungal and other infections, and Square 1 Bank, a division of Pacific Western Bank, announced they have entered into an agreement for a $20 million credit facility. Proceeds from the facility will provide working capital to support Cidara’s CD101 and CD201 programs which are in development to treat serious fungal and multi-d... 
10/24/16Cidara Therapeutics Announces Data from Studies of Novel Antifungal CD101 to be Presented at ACCP and IDWeek Annual Meetings
Data Highlight Safety and Efficacy of CD101 IV and CD101 Topical for the Treatment of Fungal Infections SAN DIEGO--(BUSINESS WIRE)--Oct. 24, 2016-- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced that data from preclinical and clinical studies evaluating its novel echinocandin antifungal CD101 as a potential treatment for serious infections will be pr... 
10/13/16Cidara Therapeutics Announces Closing of Public Offering of Common Stock, Including Exercise of Underwriter’s Option to Purchase Additional Shares
SAN DIEGO, Oct. 13, 2016 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq:CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced the closing of its previously announced underwritten public offering of 2,475,248 shares of its common stock, plus 277,389 additional shares sold pursuant to the underwriter’s partial exercise of its option to purchase additional shares, each at a price to the public of $10.10 per share. Including this option e... 
10/07/16Cidara Therapeutics Announces Pricing of Public Offering of Common Stock
SAN DIEGO, Oct. 07, 2016 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq:CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced the pricing of an underwritten public offering of 2,475,248 shares of its common stock at a price to the public of $10.10 per share. The gross proceeds to Cidara from the offering, before deducting underwriting discounts and commissions and other offering expenses, are expected to be approximately $25.0 million... 
10/06/16Cidara Therapeutics Announces Commencement of Public Offering of Common Stock
SAN DIEGO, Oct. 06, 2016 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq:CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced that it has commenced an underwritten public offering of its common stock. Cidara also expects to grant the underwriter of the offering a 30-day option to purchase additional shares of its common stock at the public offering price. The offering is subject to market conditions, and there can be no assurance as t... 
09/21/16Cidara Therapeutics Selects First Development Candidate from its CloudbreakTM Immunotherapy Discovery Platform
CD201 Demonstrates Potential to Treat Life-Threatening Multi-Drug Resistant Gram-negative Bacterial Infections SAN DIEGO--(BUSINESS WIRE)--Sep. 21, 2016-- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced that the company has selected the first development candidate from its proprietary immunotherapy discovery platform, Cloudbreak™. Cloudbreak is the fi... 
09/20/16Cidara Therapeutics to Present at the Leerink Partners Roundtable Series: Rare Disease & Immuno-Oncology
SAN DIEGO, Sept. 20, 2016 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq:CDTX), a biotechnology company developing novel anti-infectives and immunotherapies to treat fungal and other infections, today announced it will participate in a fireside chat at the Leerink Partners Roundtable Series: Rare Disease & Immuno-Oncology on Wednesday, September 28, 2016. Jeffrey Stein, Ph.D., president and chief executive officer of Cidara, is scheduled to present at 3:05 p.m. EDT (12:05 p.m. PDT).... 
09/01/16Cidara Therapeutics Announces Clinical Management Team Changes
SAN DIEGO--(BUSINESS WIRE)--Sep. 1, 2016-- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing novel anti-infectives and immunotherapies to treat fungal and other infections, announced that the company has named Taylor Sandison, M.D., M.P.H., its vice president, clinical development, to the position of acting chief medical officer, effective September 2, 2016. Dr. Sandison will replace Dirk Thye, M.D., Cidara’s previous chief med... 
08/11/16Cidara Reports Second Quarter 2016 Financial Results and Provides Corporate Update
SAN DIEGO, Aug. 11, 2016 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq:CDTX), a biotechnology company developing novel anti-infectives and immunotherapies to treat fungal and other infections, today reported financial results for the three months ended June 30, 2016 and provided an update on its corporate activities and product pipeline. “Cidara has made notable clinical progress in the second quarter and subsequently as we dosed the first patients in our STRIVE and RADIANT Phase 2 ... 
08/09/16Cidara Therapeutics Announces Presentations Addressing Vulvovaginal Candidiasis at Upcoming IDSOG Annual Meeting
Presentations Will Highlight Data from Studies of Novel Echinocandin CD101 and Reinforce the Unmet Need for Effective New VVC Treatments SAN DIEGO--(BUSINESS WIRE)--Aug. 9, 2016-- Cidara Therapeutics, Inc. (Nasdaq:CDTX), a biotechnology company developing novel anti-infectives and immunotherapies to treat fungal and other infections, today announced that data from preclinical studies evaluating its novel Phase 2 echinocandin CD101 as a topical... 
07/06/16Cidara Therapeutics to Present at the Cantor Fitzgerald Annual Healthcare Conference
SAN DIEGO, July 06, 2016 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq:CDTX), a biotechnology company developing novel anti-infectives and immunotherapies to treat fungal and other infections, today announced it will be participating in the 2nd Annual Cantor Fitzgerald Healthcare Conference on Tuesday, July 12, 2016. Jeffrey Stein, Ph.D., president and chief executive officer of Cidara, is scheduled to present at 9:30 a.m. EDT (6:30 a.m. PDT). The conference is being held in New York C... 
07/05/16Cidara Therapeutics Expands Management Team
SAN DIEGO, July 05, 2016 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq:CDTX), a biotechnology company developing novel anti-infectives and immunotherapies to treat fungal and other infections, today announced the addition of Neil Abdollahian and Matt Onaitis to the executive management team. Mr. Abdollahian joins as Chief Business Officer and Mr. Onaitis will assume the role of Chief Financial Officer and General Counsel. Previously, Mr. Abdollahian was Vice President of Corporate D... 
06/09/16Cidara Therapeutics Doses First Patient in Phase 2 Trial of CD101 Topical to Treat Vulvovaginal Candidiasis
SAN DIEGO--(BUSINESS WIRE)--Jun. 9, 2016-- Cidara Therapeutics, Inc. (Nasdaq:CDTX), a biotechnology company developing novel anti-infectives and immunotherapies to treat fungal and other infections, today announced that the first patient has been dosed in RADIANT, a Phase 2 clinical trial comparing the safety and tolerability of the novel echinocandin, CD101, to standard-of-care fluconazole for the treatment of acute vulvovaginal candidiasis (VVC). ... 
06/08/16Cidara Therapeutics to Present Data on Lead Antifungal Product Candidate CD101 at Upcoming ASM Microbe 2016
Results from Multiple Dose Phase 1 Trial of CD101 IV Supporting High-Exposure, Once-Weekly Dosing Will Be Presented For the First Time SAN DIEGO--(BUSINESS WIRE)--Jun. 8, 2016-- Cidara Therapeutics, Inc. (Nasdaq:CDTX), a biotechnology company developing novel anti-infectives and immunotherapies to treat fungal and other infections, today announced that data from preclinical and clinical studies evaluating its lead antifungal product candidate, ... 
06/02/16Cidara Therapeutics to Present at the Jefferies 2016 Healthcare Conference
SAN DIEGO, June 02, 2016 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq:CDTX), a biotechnology company developing novel anti-infectives and immunotherapies to treat fungal and other infections, today announced it will be participating in the Jefferies 2016 Healthcare Conference  on Thursday, June 9, 2016. Jeff Stein, Ph.D., president and chief executive officer of Cidara, is scheduled to present at 10:00 a.m. EDT (7:00 a.m. PDT). The conference is being held in New York City. A live ... 
05/31/16FDA Grants QIDP and Fast Track Designation to CD101 Topical, Cidara Therapeutics’ Novel Antifungal Product Candidate
-CD101 Topical designated for treatment of VVC and for prevention of recurrent VVC- SAN DIEGO--(BUSINESS WIRE)--May 31, 2016-- Cidara Therapeutics, Inc. (Nasdaq:CDTX), a biotechnology company developing novel anti-infectives and immunotherapies to treat fungal and other infections, today announced that the U.S. Food and Drug Administration (FDA) has designated the company’s novel antifungal product candidate, CD101 topical, as a Qualified Infe... 
05/12/16Cidara Reports First Quarter 2016 Financial Results and Provides Corporate Update
SAN DIEGO, May 12, 2016 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq:CDTX), a biotechnology company developing novel anti-infectives and immunotherapies to treat fungal and other infections, today reported financial results for the three months ended March 31, 2016 and provided an update on its corporate activities and product pipeline. First Quarter 2016 and Subsequent Highlights Phase 2 Candidemia Clinical Trial On Track: Cidara conducted an End-of-Phase 1 meeting with the F... 
04/06/16Cidara Therapeutics Announces Presentation of Data from its Antifungal Drug Development Programs at ECCMID 2016
Presentations to Highlight Results from the Phase 1 Study of Novel Echinocandin CD101 IV Demonstrating Excellent Safety and Supporting Once-Weekly Dosing SAN DIEGO--(BUSINESS WIRE)--Apr. 6, 2016-- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing novel anti-infectives and immunotherapies to treat fungal and other infections, today announced that data from preclinical and clinical studies of its novel echinocandin, CD... 
04/05/16Cidara Therapeutics to Present at the Needham & Company 15th Annual Healthcare Conference
SAN DIEGO, April 05, 2016 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq:CDTX), a biotechnology company developing novel anti-infectives and immunotherapies to treat fungal and other infections, today announced it will be participating in the Needham & Company 15th Annual Healthcare Conference on Tuesday, April 12, 2016. Jeff Stein, Ph.D., president and chief executive officer of Cidara, is scheduled to present at 3:00 p.m. EDT (12:00 p.m. PDT). The conference is being held in New Y... 
03/18/16Cidara Reports Fourth Quarter and Full Year 2015 Financial Results and Provides Corporate Update
SAN DIEGO, March 18, 2016 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq:CDTX), a biotechnology company developing novel anti-infectives and immunotherapies to treat fungal and other infections, today reported financial results for the three months and full year ended December 31, 2015 and provided an update on its corporate activities and product pipeline. Fourth Quarter 2015 and Subsequent Highlights Announced Positive Data from Single and Multiple Dose Phase 1 Clinical Trials... 
02/10/16Cidara Receives Orphan Drug Designation for Novel Echinocandin, CD101 IV, in Candidemia and Invasive Candidiasis
Orphan designation follows QIDP and Fast Track status for CD101 IV SAN DIEGO--(BUSINESS WIRE)--Feb. 10, 2016-- Cidara Therapeutics, Inc. (Nasdaq:CDTX), a biotechnology company developing novel anti-infectives and immunotherapies to treat fungal and other infections, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to its antifungal drug candidate, CD101 IV, for the treatment of candidemia and ... 
02/03/16Cidara Therapeutics Announces Participation in Leerink Partners 5th Annual Global Healthcare Conference
SAN DIEGO, Feb. 03, 2016 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq:CDTX), a biotechnology company developing novel anti-infectives and immunotherapies to treat fungal and other infections, today announced it will be participating in the Leerink Partners 5th Annual Global Healthcare Conference on Wednesday, February 10, 2016. Jeff Stein, Ph.D., president and chief executive officer of Cidara, is scheduled to conduct a fireside chat from 2:40 p.m.– 3:00 p.m. EST. The conference is be... 
01/11/16Cidara Therapeutics Announces Positive Data from Multiple Dose Phase 1 Clinical Trial of CD101 IV
-- Multiple Ascending Dose Study-Results Reinforce Excellent Safety and Tolerability – SAN DIEGO--(BUSINESS WIRE)--Jan. 11, 2016-- Cidara Therapeutics, Inc. (Nasdaq:CDTX), a biotechnology company developing novel anti-infectives and immunotherapies to treat fungal and other infections, today announced data from the company’s Phase 1 multiple ascending dose clinical trial of its antifungal drug candidate, CD101 IV, in healthy volunteers. CD101 ...